{
    "code": "02025214",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02025214",
    "time": "2020-09-11 10:24:47",
    "許可證字號": "衛署藥輸字第025214號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "114\/06\/15",
    "發證日期": "99\/06\/15",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202521400",
    "中文品名": "瑞復美膠囊25毫克",
    "英文品名": "Revlimid Capsules 25mg",
    "適應症": "多發性骨髓瘤。\r\n1.REVLIMID®（Lenalidomide）與dexamethasone、與bortezomib及dexamethasone、或與melphalan及prednisone合併使用治療不適合接受移植之新診斷多發性骨髓瘤（multiple myeloma，MM）成年病人。\r\n2.REVLIMID®（Lenalidomide）單一療法適用於做為已接受自體造血幹細胞移植之新診斷多發性骨髓瘤成年病人的維持治療用藥。\r\n3.REVLIMID®（Lenalidomide）與dexamethasone合併使用可治療先前已接受至少一種治療失敗之多發性骨髓瘤病人。",
    "劑型": "130膠囊劑",
    "包裝": "2-1000粒以下鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "LENALIDOMIDE",
    "限制項目": "02輸　入 1D須執行風險管理計畫 1EPhase IV Study",
    "申請商名稱": "620117G076  賽基有限公司",
    "申請商地址": "臺北市信義區松仁路32號9樓",
    "主製造廠": [
        {
            "製造廠名稱": "FCH0247000  CELGENE INTERNATIONAL SARL",
            "製造廠廠址": "ROUTE DE PERREUX 1 2017 BOUDRY SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FSG0036000  BOLLORE LOGISTICS SINGAPORE PTE. LTD.",
            "製造廠廠址": "101 ALPS AVENUE #03-01 SINGAPORE 498793",
            "製造廠公司地址": "",
            "製造廠國別": "SINGAPORE",
            "製程": ""
        }
    ],
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1008200300",
            "成分名稱": "LENALIDOMIDE",
            "含量描述": "",
            "含量": "25.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "22 x 8 (+\/-1) mm",
        "特殊劑型": "",
        "顏色": "白色",
        "特殊氣味": "",
        "刻痕": "無",
        "形狀": "長圓柱形",
        "標記一": "REV",
        "標記二": "25mg"
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Revlimid 25mg Image-107-03-19(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025214&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "Rev Chinese PIL_version 6.5 發聲困難+temp_排版-109-07-13.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025214&Seq=011&Type=9"
        },
        {
            "title": "Revlimid 25mg Labelling (2017Aug01)-107-03-19(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025214&Seq=004&Type=8"
        },
        {
            "title": "外盒中文小標籤_ 25毫克-105-04-19.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025214&Seq=003&Type=8"
        }
    ]
}